Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ARID1A”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)Looking for participantsNCT06617923
What this trial is testing

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Who this might be right for
Ovary CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 18
Testing effectiveness (Phase 2)Ended earlyNCT02059265
What this trial is testing

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Who this might be right for
Endometrial Clear Cell AdenocarcinomaOvarian Clear Cell CystadenocarcinomaRecurrent Fallopian Tube Carcinoma+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Looking for participantsNCT04065269
What this trial is testing

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Who this might be right for
Gynaecological Cancers
Institute of Cancer Research, United Kingdom 174
Testing effectiveness (Phase 2)Ended earlyNCT04493619
What this trial is testing

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Who this might be right for
Gynecologic NeoplasmsEpithelial Ovarian Cancer
Opna Bio LLC 37
Testing effectiveness (Phase 2)Looking for participantsNCT04104776
What this trial is testing

Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Who this might be right for
Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more
Novartis Pharmaceuticals 275
Not applicableStudy completedNCT04872036
What this trial is testing

Prognostic Biomarkers in Patients With Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Hellenic Cooperative Oncology Group 66
Testing effectiveness (Phase 2)Looking for participantsNCT05023655
What this trial is testing

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Who this might be right for
Solid TumorARID1A Gene Mutation
Prisma Health-Upstate 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04953104
What this trial is testing

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+29 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)UnknownNCT04284202
What this trial is testing

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Who this might be right for
NSCLC Stage IVARID1APD-1
The Affiliated Hospital of Qingdao University 30
Early research (Phase 1)Study completedNCT03297424
What this trial is testing

PLX2853 in Advanced Malignancies.

Who this might be right for
Small Cell Lung CancerUveal MelanomaOvarian Clear Cell Carcinoma+5 more
Opna Bio LLC 49
Testing effectiveness (Phase 2)Looking for participantsNCT06518564
What this trial is testing

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Who this might be right for
Endometrial CancerARID1A Gene MutationRecurrent Endometrial Carcinoma
Panagiotis Konstantinopoulos, MD, PhD 25
Very early researchNot Yet RecruitingNCT06824363
What this trial is testing

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

Who this might be right for
Solid Tumor, AdultMalignant Solid TumorStomach Adenocarcinoma+1 more
University of California, Irvine 34
Testing effectiveness (Phase 2)Ended earlyNCT05523440
What this trial is testing

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Ovarian CarcinomaARID1A Gene Mutation
University of Oklahoma 7
Testing effectiveness (Phase 2)Looking for participantsNCT05490472
What this trial is testing

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Who this might be right for
Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC+2 more
Jacobio Pharmaceuticals Co., Ltd. 102
Early research (Phase 1)WithdrawnNCT04315155
What this trial is testing

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Who this might be right for
Metastatic Adenocarcinoma
University of Utah
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07213557
What this trial is testing

Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy

Who this might be right for
Advanced or Metastatic Gastrooesophageal Carcinoma
National Cancer Institute, Naples 84
Early research (Phase 1)Active Not RecruitingNCT05226507
What this trial is testing

Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Who this might be right for
Advanced Solid TumorOvarian CancerOvarian Clear Cell Carcinoma+5 more
Nuvectis Pharma, Inc. 45
Testing effectiveness (Phase 2)WithdrawnNCT05690035
What this trial is testing

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Who this might be right for
Metastatic Colorectal CancermCRC
Sun Yat-sen University
Early research (Phase 1)Looking for participantsNCT05950464
What this trial is testing

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04957615
What this trial is testing

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Who this might be right for
Metastatic Malignant Solid NeoplasmUnresectable Solid Neoplasm
M.D. Anderson Cancer Center 16